Mintal Tracker Lets Users See Their Dreams – Again
AI-driven feature automatically generates an image of the user's dream by utilizing key words, enabling the ability to physically share their dreams SUNNYVALE, Calif., Nov. 21, 2022 /PRNewswire/ -- Mintal Tracker, a sleep tracking app driven by artificial intelligence (AI) technology that offers a scientific approach to healthier sleep, announced an AI-generated art feature called "Draw My Dream," which...
Professor László Tabár Joins DetectedX as the Medical Director of Breast Cancer Imaging
DetectedX Bolsters Executive Team with Internationally Renowned Physician, Academic and Educator to Expand Breast Imaging Educational Content on the Company's Radiology Online Learning Platform SYDNEY, Nov. 21, 2022 /PRNewswire/ -- DetectedX, leaders in intelligent interactive educational technology, announced today that Professor László Tabár, a Nobel Prize Nominee and visionary physician, academic and educator,...
Triastek Receives FDA IND Clearance for 3D Printed Medicine for the Treatment of Ulcerative Colitis
Triastek's third FDA IND clearance for a 3D printed medicine T21, a novel potential treatment capable of colon-targeted drug delivery NANJING, China, Nov. 21, 2022 /PRNewswire/ -- Triastek, Inc. ("Triastek") a global healthcare company pioneering 3D printing of pharmaceuticals with its proprietary technology, Melt Extrusion Deposition (MED®), announced today that...
Immorna Receives IND Clearance to Conduct a Phase 1/2 Study of JCXH-221, a Broadly Protective mRNA-Based COVID-19 Vaccine
MORRISVILLE, N.C., Nov. 21, 2022 /PRNewswire/ -- Immorna, a rapidly expanding biotechnology company, focusing on the development of multi-platform RNA-based therapeutics and vaccines, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to conduct a Phase 1/2 multi-center study of JCXH-221, a lipid nanoparticle (LNP) complexed broadly protective mRNA vaccine against...
Cambrex to Acquire Snapdragon Chemistry, a Leader in Continuous Flow API Development Services
EAST RUTHERFORD, N.J., Nov. 21, 2022 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, today announced that it has entered into a definitive agreement to acquire Snapdragon Chemistry, a leading US-based provider of chemical process...
APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film Festival
GENEVA, Nov. 21, 2022 /PRNewswire/ -- RELIEF THERAPEUTICS Holding SA (SIX: RLF) (OTCQB: RLFTF) (RLFTD) ("Relief"), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent protected products in selected specialty, rare and ultra-rare disease areas on a global basis, today announced that its wholly owned subsidiary APR Applied Pharma Research SA ("APR") has been nominated as a...
Ainos Publishes Preclinical Data Demonstrating its VELDONA Formulation’s Potential as Treatment Candidates for the Most Common Medical Conditions for Companion Animals
VELDONA® interferon-alpha formulation has shown potential as a treatment candidate for feline chronic gingivostomatitis and canine atopic dermatitis Ainos advances its product pipeline as it targets commencing clinical studies during the second quarter of 2023 SAN DIEGO, Nov. 21, 2022 /PRNewswire/ -- Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development...
OLON, INTERNATIONAL API SUPPLIER, RELEASES THE NEW SUSTAINABILITY REPORT 2022 CONFIRMING THE PROGRESS OF ITS SUSTAINABILITY IN THE FOCUS AREAS OF ENVIRONMENT, SUPPLY CHAIN, PEOPLE, COMMUNITY ENGAGEMENT, PRODUCTION
"Our ambition is to promote a more sustainable production of APIs, meeting the highest standards of quality" Paolo Tubertini, CEO of the Group, commented "To achieve this, we are investing in people, in innovation and technology processes, endorsing the sustainable development goals proposed by the UN 2030 Agenda" MILAN, Nov. 21,...
Nona Biosciences Enters into HCAb Based Drug Discovery Collaboration Agreement with Dragonfly Therapeutics
CAMBRIDGE, Mass., Nov. 21, 2022 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited committed to providing a total solution from "Idea to IND" ("I to ITM"), today announced that it has entered into a collaboration agreement with Dragonfly Therapeutics based on Nona's proprietary fully human heavy chain only antibody (HCAb)...
Lianhua Respiratory Health Products to Assure the Smooth Holding of Hainan International Health Industry Expo
SHIJIAZHUANG, China, Nov. 21, 2022 /PRNewswire/ -- The 6th Hainan International Health Industry Expo kicked off on November 18th, in Haikou City, China's Hainan Province. With the theme of "Construct a Global Health System, Draw a Beautiful Future for Hainan Free Trade Port", this year's event will hold 30 high-level forums, famous medical scientists, doctors, experts, and entrepreneurs from...
